Long-term outcomes in dogs with sinonasal aspergillosis treated with intranasal infusions of enilconazole.

Abstract

Long-term outcomes (mean 38+/-17 months) were evaluated in 27 dogs with sinonasal aspergillosis after successful medical treatment using intranasal infusions of 1% or 2% enilconazole (1%, n=15; 2%, n=12). Long-term outcomes with both treatment protocols were good, with half of the dogs being asymptomatic throughout the follow-up period. The remaining dogs showed mild clinical signs compatible with chronic rhinitis/sinusitis. These clinical signs were interpreted as chronic lymphoplasmacytic rhinitis/sinusitis and episodes of bacterial rather than fungal infection. Three dogs had confirmed reinfection or relapse 2 to 36 months after clinical resolution.

• Authors: Simone Schuller, Cecile Clercx
• Journal: Journal of the American Animal Hospital Association (J Am Anim Hosp Assoc) 2007 Jan-Feb Vol. 43 Issue 1 Pg. 33-8 ISSN: 1547-3317 [Electronic] United States
• PMID: 17209083 (Publication Type: Journal Article)

Chemical References

• Fungicides, Industrial
• Imidazoles
• enilconazole

Topics

• Administration, Topical
• Animals
• Aspergillosis (drug therapy, veterinary)
• Dog Diseases (drug therapy, microbiology)
• Dogs
• Endoscopy (veterinary)
• Female
• Fungicides, Industrial (administration & dosage, therapeutic use)
• Imidazoles (administration & dosage, therapeutic use)
• Male
• Paranasal Sinus Diseases (drug therapy, microbiology, veterinary)
• Retrospective Studies
• Time Factors
• Treatment Outcome